We are live on
!
Find out more
RS
R Squared Portfolio holdings
AUM
$182M
1-Year Est. Return
18.52%
This Fund
S&P 500
This Quarter
Est. Return
+0.01%
1 Year Est. Return
+18.52%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$103M
AUM Growth
–
Cap. Flow
+$107M
Cap. Flow
% of AUM
104.12%
Top 10 Holdings %
Top 10 Hldgs %
10.53%
Holding
1,571
New
1,571
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$2.59M |
| 2 |
FirstEnergy
FE
|
+$1.2M |
| 3 |
Eaton
ETN
|
+$1.08M |
| 4 |
Consolidated Edison
ED
|
+$1.06M |
| 5 |
Verizon
VZ
|
+$1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 18.64% |
| 2 | Technology | 14.58% |
| 3 | Industrials | 13.88% |
| 4 | Consumer Discretionary | 12.94% |
| 5 | Healthcare | 11.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Robinhood
HOOD
$89.7B
| $212K | 0.21% |
+5,700
| New | +$184K |
|
102
Granite Construction
GVA
$5.43B
| $211K | 0.2% |
+2,400
| New | +$216K |
|
103
Everest Group
EG
$15.1B
| $207K | 0.2% |
+570
| New | +$213K |
|
104
Freeport-McMoran
FCX
$83.9B
| $206K | 0.2% |
+5,408
| New | +$242K |
|
|
ITCI
105
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $205K | 0.2% |
+2,450
| New | +$201K |
|
106
Corebridge Financial
CRBG
$14.4B
| $204K | 0.2% |
+6,830
| New | +$211K |
|
107
Parker-Hannifin
PH
$120B
| $204K | 0.2% |
+320
| New | +$212K |
|
|
AMED
108
DELISTED
Amedisys
AMED
| $203K | 0.2% |
+2,240
| New | +$206K |
|
109
NMI Holdings
NMIH
$3.27B
| $203K | 0.2% |
+5,510
| New | +$214K |
|
110
Evercore
EVR
$13.2B
| $202K | 0.2% |
+730
| New | +$207K |
|
111
Northrop Grumman
NOC
$74.1B
| $202K | 0.2% |
+430
| New | +$216K |
|
112
Sanofi
SNY
$107B
| $202K | 0.2% |
+4,180
| New | +$213K |
|
113
Federal Signal
FSS
$7.11B
| $200K | 0.2% |
+2,170
| New | +$199K |
|
114
GE Vernova
GEV
$284B
| $197K | 0.19% |
+600
| New | +$188K |
|
115
Hartford Financial Services
HIG
$38.4B
| $197K | 0.19% |
+1,800
| New | +$209K |
|
116
Novartis
NVS
$293B
| $196K | 0.19% |
+2,010
| New | +$214K |
|
117
Rollins
ROL
$21.7B
| $194K | 0.19% |
+4,180
| New | +$205K |
|
118
Varonis Systems
VRNS
$5.46B
| $194K | 0.19% |
+4,360
| New | +$227K |
|
119
Boeing
BA
$169B
| $193K | 0.19% |
+1,090
| New | +$171K |
|
120
Seagate
STX
$178B
| $192K | 0.19% |
+2,220
| New | +$223K |
|
121
Synchrony
SYF
$24.8B
| $191K | 0.19% |
+2,940
| New | +$180K |
|
122
Philip Morris
PM
$301B
| $190K | 0.19% |
+1,580
| New | +$199K |
|
123
Texas Roadhouse
TXRH
$13B
| $188K | 0.18% |
+1,040
| New | +$196K |
|
124
Thomson Reuters
TRI
$42B
| $186K | 0.18% |
+1,142
| New | +$192K |
|
125
CVS Health
CVS
$137B
| $186K | 0.18% |
+4,140
| New | +$232K |
|
Similar funds
NED
CFG
CFG
WCM
OWA
TFP
HIMS
AFS
R Squared's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for R Squared, which disclosed 1,571 positions worth $103M. Its ten largest holdings account for 11% of the portfolio.
Its largest position is Linde: 5,681 shares worth $2.38M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, followed by Technology and Industrials.
- R Squared's largest Q4 2024 buy was Linde: 5,681 shares worth $2.38M.
- R Squared's ten largest holdings make up 11% of its $103M portfolio in Q4 2024.
- R Squared disclosed 1,571 positions in Q4 2024, its first 13F filing on record.
Based on R Squared's 13F filing for Q4 2024, filed 23 Jan 2025.